Characteristicst	SMLP + curcumin-based drug (N tot: 9)	Only SMLP (N. tot: 15)
Sex Male Female	-5 (55%) -4 (45%)	-8 (53%) -7 (47%)
Age (mean), years	65 (55-71)	63 (56-74)
Laterality Right eye Left eye	5 (55%) 4 (45%)	-8 (53%) -7 (47%)
Durationofdiabetes(mean), years	11 (8-14)	12 (9-14)
Insulin used	4 (45%)	7 (47%)
Last HbA1c measurement before enrolling (mean), %	7,1 % (6,8% - 7,4%)	7,2% (6,9% - 7,5%)
Best Corrected Visual Acu-ity (mean)	6/10 (4/10- 8/10)	5/10 (4/10 – 7/10)
Central macular thickness (μm) -350 - 399 -400 – 499	- 5 (55%) - 4 (45%)	- 9 (60%) - 6 (40%)
" Prior treatment for DME Prior focal/grid laser photocoagulation for DME Prior anti-VEGF therapyfor DME	- 4 (44%) - 2 (22%)	- 7 (47%) - 4 (27%)

Table 1: Baseline Patients and Ocular characteristics

	"ctrl"	"ivt"	"p"
"CMT at time zero, baseline (mean (SD))"	396.67 (73.21)	414.13 (48.82)	0.489
"CMT at time zero, baseline (median [IQR])"	410.00 [395.00, 430.00]	425.00 [391.00, 444.50]	0.531
"month4 (mean (SD))"	404.88 (24.99)	345.38 (56.16)	0.011
"month4.imp (mean (SD))"	384.44 (65.60)	355.67 (58.65)	0.277
"month4 (median [IQR])"	400.00 [395.00, 419.25]	370.00 [307.00, 386.00]	0.008
"month4.imp (median [IQR])"	400.00 [380.00, 419.00]	372.00 [320.50, 395.00]	0.169